Filing Flows › Comparisons › EDIT vs STRO
Editas Medicine vs Sutro Biopharma: EDIT and STRO compared
Editas Medicine is the larger company: $10.4M of revenue in its latest quarter (Q3 2026) against $9.8M for Sutro Biopharma (Q2 2026). Editas Medicine is growing faster (+37% against -85% a year earlier). Editas Medicine is more profitable, with an operating margin of -234.3% against -303.8%.
Where the money goes: EDIT and STRO
Editas Medicine (EDIT) · Q3 2026
Editas Medicine, Q3 2026: revenue $10.4M (+37% year over year), operating margin -234.3%, net loss $23.4M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
Sutro Biopharma (STRO) · Q2 2026
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
| Editas Medicine (EDIT) | Sutro Biopharma (STRO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $10.4M | $9.8M |
| Revenue growth, Y/Y | +37% | -85% |
| Operating margin | -234.3% | -303.8% |
| Net earnings | −$23.4M | −$38.5M |
| Net margin | -225.7% | -391.6% |
| Operating cash flow | −$21.2M | −$38.3M |
Questions
Which is bigger, Editas Medicine or Sutro Biopharma?
Editas Medicine is the larger company: $10.4M of revenue in its latest quarter (Q3 2026) against $9.8M for Sutro Biopharma (Q2 2026).
Is Editas Medicine or Sutro Biopharma growing faster?
Editas Medicine is growing faster (+37% against -85% a year earlier).
Which is more profitable, Editas Medicine or Sutro Biopharma?
Editas Medicine is more profitable, with an operating margin of -234.3% against -303.8%.
More: Editas Medicine earnings · how Editas Medicine makes money · Sutro Biopharma earnings · how Sutro Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.